Weight Loss
Tirzepatide
10mg
$85
Dual GLP-1/GIP receptor agonist for metabolic optimization, appetite regulation, and body composition improvement.
- Tested by Freedom Diagnostics — independent US lab
- COA published with every lot
- Shipped from the US
For in-vitro research use only. Not for human or veterinary consumption, diagnostic, or therapeutic use.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity, tirzepatide demonstrated up to 22.5% weight reduction in the SURMOUNT-1 trial. Its dual mechanism provides complementary metabolic benefits that surpass GLP-1 agonism alone.
Tirzepatide simultaneously activates GIP receptors — enhancing glucose-dependent insulin secretion and suppressing glucagon — and GLP-1 receptors, which slow gastric emptying and reduce appetite via hypothalamic signaling. GIP receptor activation also promotes adipocyte lipid utilization and reduces visceral fat accumulation, producing synergistic metabolic effects beyond GLP-1 monotherapy.
- Molecular Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight
- ~4.8 kDa
- Form
- Lyophilized peptide powder
- Solubility
- Soluble in bacteriostatic water
- Dosage Range
- 2.5–15mg weekly (research context)
- Plasma Half-Life
- ~5 days
- Bioavailability
- ~80% subcutaneous
Certificate of analysis
Independent third-party report for the lot you receive — identity and purity. Available on request with your order; we'll email it back the same business day.
Cold-chain when required
Temperature-sensitive peptides ship with insulation and coolant. Store as indicated on the vial. Stability notes included with the order.
For research only
Sold for in-vitro research and laboratory use. Not for human or veterinary consumption. We don't advise on protocols or dosing.
- [01]
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Jastreboff A.M. et al. · New England Journal of Medicine · 2022
Tirzepatide produced a mean weight reduction of up to 22.5% over 72 weeks in adults with obesity, significantly exceeding placebo.
- [02]
Dual GIP and GLP-1 receptor agonist tirzepatide improves glycemic control
Frias J.P. et al. · Lancet · 2021
Tirzepatide demonstrated superior HbA1c reduction and weight loss compared to semaglutide in a head-to-head Phase 3 trial.
- [03]
GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea
Samms R.J. et al. · Diabetes · 2020
Co-activation of GIP receptors reduced the nausea side-effect profile of GLP-1 agonism while preserving or enhancing metabolic benefits.
